Decreased levels of guanosine 3′, 5′‐monophosphate (c<scp>GMP</scp>) in cerebrospinal fluid (<scp>CSF</scp>) are associated with cognitive decline and amyloid pathology in <scp>A</scp>lzheimer's disease

Abstract

These results support the potential involvement of cGMP in the pathological and clinical development of AD. The cGMP reduction in early stages of AD might participate in the aggravation of amyloid pathology and cognitive decline.